EUCTR2010-022798-32-IT进行中（未招募）不适用
Double-blind, randomised, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single oral administration of four different combination doses of DKP.TRIS with TRAM.HCl in comparison with the single agents, on moderate to severe pain following impacted third mandibular molar tooth extraction - ND
MENARINI RICERCHE S.P.A.0 个研究点目标入组 600 人开始时间: 2010年12月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients aged 18 to 70 years. 2. BMI between 18 kg/m2 and 30 kg/m2. 3. Females participating in the study must be either: Of non-childbearing potential, i.e. surgically sterilised or postmenopausal with amenorrhea for at least 2 years prior the study. If indicated, this should be confirmed by follicle-stimulating hormone and estradiol levels (according to local laboratory range). ? Willing to use a highly effective contraceptive method (failure rate < 1% per year) during the entire study period. Appropriate forms of contraception are defined as: i) abstinence- the lifestyle of the female should be such that there is complete abstinence from intercourse from at least the commencement of their last menstrual period prior to dosing with study treatment and continue to the first menstrual period after treatment or 15 days after the last dose of medication whichever is the longest. ii) established use of oral, injected, or implanted hormonal methods of contraception from at least the commencement of their last menstrual period prior to dosing with study treatment and continue to the first menstrual period after treatment. iii) documented placement of an intrauterine device (IUD). iv) male partner sterilisation (vasectomy) prior to the female patient`s entry into the study and is the sole partner for the female patients. 4. Females of childbearing potential must have a negative pregnancy test at Screening. 5. Scheduled for outpatient surgical extraction -under local anaesthesia- of third mandibular molar teeth, with at least one of which is fully or partially impacted in the mandible requiring bone manipulation (e.g. grade ? 5 of Pell-Gregory and Winter scale). 6. Mentally competent, able to give written informed consent prior to study entry and compliant to undergo all visits and procedures scheduled in the study and record information required by protocol. 7. Medical history and physical examination normal or without clinically relevant abnormalities on the investigator’s judgement. After surgery, patients meeting the following criteria will be eligible to be randomised into the study: 8. No clinically relevant abnormalities in vital signs, laboratory findings and 12-lead ECG, as per investigator’s judgement. 9. No intake of analgesics (including prescription and over the counter drugs) within 24h prior to the surgery. 10. No intake of prohibited medication (please refer to exclusion criterion # 10). 11. Females of childbearing potential must have a negative pregnancy test before randomisation. 12. Patients with no complication during the surgery, with overall duration of surgery not longer than 1 hour and not requiring re-anaesthesia. 13. Patients experiencing pain of moderate or higher intensity in the first four hours after the end of surgery (VAS score ? 40 mm and VRS score ? 2). 14. Patients agreeing not to take analgesics other than protocol defined rescue medication during the treatment period (up to 24 hours post-dosing).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with history of allergy or hypersensitivity to the study drugs/rescue medication or to any other NSAIDs, opioids or acetyl salicylic acid. 2. Patients with history of asthma, bronchospasm, acute rhinitis, nasal polyps, uricaria or angioneurotic oedema. 3. Patients with history of peptic ulcer, gastrointestinal disorders by NSAIDs, gastrointestinal bleeding or other active bleedings. 4. Patients with moderate to severe renal, hepatic or cardiac dysfunction. 5. Patients with coagulation disorders. 6. Patients with uncontrolled epilepsy. 7. Patients with Crohn’s disease or ulcerative colitis. 8. Patients with history of drug or alcohol abuse. For the purpose of the study, alcohol abuse is defined as follows for males and females, respectively: - an average weekly intake of >21 and >14 units - or an average daily intake of >3 and >2 units One unit corresponds to approx 125 ml wine, 200 ml beer, 25 ml spirit. 9. Patients who are judged by the investigator not to be suitable candidates for study treatment and rescue medication based on medical history, concomitant medication and concurrent systemic disease as described in the product labelling (i.e. warnings, precaution, contraindication and adverse events) of dexketoprofen, tramadol, ibuprofen and paracetamol. 10. Patients who are unable to refrain from alcohol, psychoactive drugs and sedatives (e.g. benzodiazepines) and other prohibited medication as listed below within 48 hours or 5 half-lives (whichever is the longer) prior to the start of surgery and for 24 hours post-dosing. For analgesic use ONLY, a minimum of 24 hours must elapse prior to the start of surgery. For MAO inhibitors, a minimum of 14 days must elapse prior to the start of surgery. Prohibited medication includes the following: o Analgesic drugs (other NSAIDs and opioids). o Anticoagulants, thrombolytic and antiplatelet agents. o Corticosteroids. o MAO inhibitors. o Antiepileptic drugs. o Antipsychotics. o Serotonin reuptake inhibitors and tricyclic antidepressants. o Lithium. o Metotrexate. o Sulphonamides. 11. Patients using and not suitable for withdrawing other prescription or non prescription drugs which are expected to interfere with the study treatment and procedures or compromise patient safety as described in the product labelling of study treatments/rescue medication, within 48 hours or 5 half-lives (whichever is the longer) prior to the start of surgery and for 24 hours post-dosing. 12. Patients receiving concomitant treatment with other investigational drugs or who have participated in other clinical trial within 4 weeks before the study enrolment. 13. Pregnant or breastfeeding women. A pregnancy test will be performed to all women of childbearing potential at the Screening and Randomisation Visits and a negative result must be obtained to enroll the patient into the study. 14. Patients who are not able to understand the study nature for any reason (cultural level, language comprehension…) or that the investigator suspects that they are not going to collaborate with the study procedures (e.g. patients with excessive anxiety related to previous negative dental experiences). 15. Patients with a history of any illness or condition that, in the opinion of the investigator, might pose a risk to the patient or confound the results of the study (e.g. patients with acute pain of any other origin or localization at the time of surgery).
研究者
相似试验
进行中（未招募）
1 期
Randomized, double-blind, placebo and active controlled study of the activity ofSAR407899A single-dose on the ability to increase duration of penile rigidity,under experimental condition, in patients with mild to moderate erectiledysfunction - RHOKETMild to moderate erectile dysfunctionMedDRA version: 11.1Level: LLTClassification code 10061461Term: <Manually entered code. Term in E.1.1>EUCTR2009-009936-56-FRsanofi-aventis recherche et développement24
暂停
不适用
Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) study with ENX-201Multiple Sclerosis (relapses)NL-OMON23997EnhanX Biopharm Inc.12
进行中（未招募）
不适用
Clinical trial to evaluate the clinical effect and safety of a triple combination of ibuprofen, magnesium and vitamin C in the treatment of acute pain in temporomandibular disorders (TMD).Temporomandibular joint dysfunction syndrome.EUCTR2014-003790-41-ESSpherium Biomed
已完成
不适用
Double-blind, placebo- and active-controlled, randomized, single-ascending dose study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT-462206 in healthy male subjectssleep disturbance10040998insomniaNL-OMON35433Actelion Pharmaceuticals64
进行中（未招募）
不适用
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensionEstudio aleatorizado, en doble ciego, controlado con producto activo y con placebo, de grupos paralelos y multicéntrico, para evaluar la eficacia y la seguridad de distintas dosis de CG5503 en formulación de liberación inmediata en el tratamiento del dolor agudo consecuencia de la cirugía de artroplastia total de cadera, seguido por una extensión abierta de carácter voluntariopainMedDRA version: 8.1Level: LLTClassification code 10033371Term: PainEUCTR2006-004513-18-ESJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100